<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR68">
 <label>68.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Newsted</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Banerjee</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Watt</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Nersesian</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Truesdell</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Blazer</surname>
    <given-names>LL</given-names>
   </name>
   <name>
    <surname>Cardarelli</surname>
    <given-names>L</given-names>
   </name>
   <name>
    <surname>Adams</surname>
    <given-names>JJ</given-names>
   </name>
   <name>
    <surname>Sidhu</surname>
    <given-names>SS</given-names>
   </name>
   <name>
    <surname>Craig</surname>
    <given-names>AW</given-names>
   </name>
  </person-group>
  <article-title>Blockade of TGF-beta signaling with novel synthetic antibodies limits immune exclusion and improves chemotherapy response in metastatic ovarian cancer models</article-title>
  <source>Oncoimmunology</source>
  <year>2019</year>
  <volume>8</volume>
  <issue>2</issue>
  <fpage>e1539613</fpage>
  <pub-id pub-id-type="doi">10.1080/2162402X.2018.1539613</pub-id>
  <?supplied-pmid 30713798?>
  <pub-id pub-id-type="pmid">30713798</pub-id>
 </element-citation>
</ref>
